Here's a thread regarding investor expectations for $BLU's upcoming phase 2 data. I don't believe that the BLU mgmt and analyst articulated expectations are what investors are ACTUALLY hoping for. Per recent corporate pres, that "37%" from $MRK is the key efficacy benchmark.